Five year iron changes in relapsing-remitting multiple sclerosis deep gray matter compared to healthy controls.

Abstract:

BACKGROUND:Relapsing-Remitting MS (RRMS) Deep Grey Matter (DGM) 5 year changes were examined using MRI measures of volume, transverse relaxation rate (R2*) and quantitative magnetic susceptibility (QS). By applying Discriminative Analysis of Regional Evolution (DARE), R2* and QS changes from iron and non-iron sources were separated. METHODS:25 RRMS and 25 age-matched control subjects were studied at baseline and 5-year follow-up. Bulk DGM mean R2* and QS of the caudate nucleus, putamen, thalamus and globus pallidus were analyzed using mixed factorial analysis (α = 0.05) with sex as a covariate, while DARE employed non-parametric analysis to study regional changes. Regression/correlation analysis was performed with disease duration and MS Severity Score (MSSS). RESULTS:No significant change in Extended Disability Status Score was found over 5 years (baseline = 2.4 ± 1.2; follow-up = 2.8 ± 1.3). Significant time effects were found for R2* in the caudate (Q = 0.000008; η2 = 0.36), putamen (Q = 0.0000007; η2 = 0.43), and globus pallidus (Q = 0.0000007; η2 = 0.43), while significant longitudinal effects were only found for QS in the putamen (Q = 0.002; η2 = 0.22). Significant bulk interaction was only found for thalamus volume (Q = 0.02; η2 = 0.20). Iron decrease was the only detected significant effect using DARE, and the highest significant DARE effect size was mean thalamus R2* iron decrease (Q = 0.002; η2 = 0.26). No significant correlations or regressions were demonstrated with clinical measures. CONCLUSIONS:Thalamic atrophy was the only bulk effect that demonstrated different rates of changes over 5 years compared to age-matched controls. DARE Iron decrease in regions of the caudate, putamen, and thalamus were prominent features in stable RRMS over 5 years.

authors

Elkady AM,Cobzas D,Sun H,Seres P,Blevins G,Wilman AH

doi

10.1016/j.msard.2019.05.028

subject

Has Abstract

pub_date

2019-08-01 00:00:00

pages

107-115

eissn

2211-0348

issn

2211-0356

pii

S2211-0348(19)30232-9

journal_volume

33

pub_type

杂志文章
  • Pain-related illness intrusiveness is associated with lower activity engagement among persons with multiple sclerosis.

    abstract:BACKGROUND:Pain can interfere with the daily functioning of persons with multiple sclerosis (PwMS). Furthermore, beliefs about pain and activity engagement are reliably associated with persons' experience of chronic pain. This study aimed to explore the extent to which different aspects of PwMS' activity engagement is ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.101882

    authors: Gromisch ES,Kerns RD,Beauvais J

    更新日期:2020-02-01 00:00:00

  • Chronic lung disease and multiple sclerosis: Incidence, prevalence, and temporal trends.

    abstract:OBJECTIVES:We aimed to estimate the incidence and prevalence of chronic lung disease (CLD), including asthma and chronic obstructive pulmonary disease, in the MS population versus a matched cohort from the general population. METHODS:We used population-based administrative data from four Canadian provinces to identify...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.05.009

    authors: Marrie RA,Patten S,Tremlett H,Svenson LW,Wolfson C,Yu BN,Elliott L,Profetto-McGrath J,Warren S,Leung S,Jette N,Bhan V,Fisk JD

    更新日期:2016-07-01 00:00:00

  • Real-world incidence of fingolimod-associated macular oedema.

    abstract:BACKGROUND:Fingolimod (Gilenya, Novartis, Basel Switzerland) 0.5 mg orally once-daily is widely used for relapsing-remitting multiple sclerosis. Patients are usually screened four months after starting fingolimod for fingolimod-associated macular oedema (FAME). Large registration trials with stringent eligibility crite...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102125

    authors: Goh LY,Kirthi V,Silber E,Harvey JP,Jackson TL

    更新日期:2020-07-01 00:00:00

  • The prevalence of cognitive impairment in patients with neuromyelitis optica spectrum disorders (NMOSD): A systematic review and meta-analysis.

    abstract:OBJECTIVE:To estimate pooled prevalence of cognitive impairment in neuromyelitis opticaspectrum disorders (NMOSD) cases. METHODS:We searched PubMed, Scopus, EMBASE, Web of Science, and google scholar. We also searched the gray literature including references of the included studies, and conference abstracts which were...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2021.102757

    authors: Moghadasi AN,Mirmosayyeb O,Mohammadi A,Sahraian MA,Ghajarzadeh M

    更新日期:2021-01-15 00:00:00

  • Erythroblastaemia in natalizumab-treated patients with multiple sclerosis.

    abstract:BACKGROUND:Natalizumab is a monoclonal antibody that significantly reduces the occurrence of relapses in relapse-remitting multiple sclerosis (RRMS) patients. Early papers on the clinical use of natalizumab in RRMS patients reported erythroblastemia as occasional and transient. OBJECTIVES:to determine the prevalence a...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.05.020

    authors: La Gioia S,Seghezzi M,Barcella V,Dominoni P,Mecca T,Frigeni B,Conti MZ,Vedovello M,Vidali M,Rottoli M,Buoro S

    更新日期:2016-07-01 00:00:00

  • The long-term impact of multiple sclerosis on the risk of divorce.

    abstract:BACKGROUND:Several studies have investigated the impact of multiple sclerosis (MS) on the risk of divorce. However, current evidence is inconclusive and limited by e.g. small sample populations, short follow-up, and/or lack of a control group. The objective of this retrospective, observational study was to estimate the...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.07.002

    authors: Landfeldt E,Castelo-Branco A,Svedbom A,Löfroth E,Kavaliunas A,Hillert J

    更新日期:2018-08-01 00:00:00

  • End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines?

    abstract:BACKGROUND:Many natalizumab treated patients experience end of dose interval (EDI) symptoms towards the end of the administration cycle. Natalizumab has previously shown to influence cytokine profiles in relapsing remitting MS patients. We hypothesize that EDI symptoms might be explained by variability in serum cytokin...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102020

    authors: Cathérine D,Annelien P,Anne S,Luc A,Liesbeth VH,Gerlo S,Guy L

    更新日期:2020-06-01 00:00:00

  • Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort.

    abstract:BACKGROUND:Neuromyelitis optica spectrum disorder (NMOSD) is a complex disease characterized by a severe inflammation of the central nervous system (CNS). This disease typically manifests with recurrent optic neuritis (ON) and acute transverse myelitis (ATM). The clinical and radiological spectrum of NMOSD is little kn...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102208

    authors: Edgar Patricio CD,Eleanor THG,Francisco José CZ,Gabriela ACM,Hyland AO,Fernando GL,María TA,Beatriz N,Marcos SD,Alfredo GPW

    更新日期:2020-09-01 00:00:00

  • Development of a brief clinician-reported outcome measure of multiple sclerosis signs and symptoms: The Clinician Rating of Multiple Sclerosis (CRoMS).

    abstract:OBJECTIVE:No available assessment tool offers a brief and psychometrically sound way for clinicians to quantify assessment of MS in a typical office visit. The objective of this study was to develop a brief clinician-reported outcome measure of MS signs and symptoms to standardize and quantify assessments that occur du...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.06.024

    authors: Matza LS,Stewart KD,Phillips G,Delio P,Naismith RT

    更新日期:2019-10-01 00:00:00

  • Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review.

    abstract::Multiple sclerosis (MS) is an inflammatory, demyelinating, neurodegenerative, immune-mediated disease primarily diagnosed in early adulthood. Multiple sclerosis mostly impacts women of reproductive potential, with pregnancy and birth outcomes being major concerns for many patients. While there is ample evidence that t...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2019.04.003

    authors: Coyle PK,Oh J,Magyari M,Oreja-Guevara C,Houtchens M

    更新日期:2019-07-01 00:00:00

  • Unilateral arm rehabilitation for persons with multiple sclerosis using serious games in a virtual reality approach: Bilateral treatment effect?

    abstract::IMPAIRED: arm function and loss of manual dexterity can lead to decreased independence in activities of daily living in persons with Multiple Sclerosis (MS). In this study we verified the feasibility and efficacy of a serious games approach to supervised upper limb rehabilitation of the more affected arm in persons wi...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.07.010

    authors: Jonsdottir J,Perini G,Ascolese A,Bowman T,Montesano A,Lawo M,Bertoni R

    更新日期:2019-10-01 00:00:00

  • An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis.

    abstract:BACKGROUND:Notoriously the treatment of multiple sclerosis (MS) is based on the use of several different drugs, characterized by a diverse mechanism of action, efficacy and safety. Recently, progress has been made towards developing new oral immunotherapies, and dimethyl fumarate is the third oral agent approved for th...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.03.009

    authors: Lorefice L,Fenu G,Cabras F,Frau J,Coghe GC,Loi L,Marrosu MG,Cocco E

    更新日期:2016-05-01 00:00:00

  • Racial differences in retinal neurodegeneration as a surrogate marker for cortical atrophy in multiple sclerosis.

    abstract:BACKGROUND:Multiple sclerosis (MS) has both an inflammatory and a neurodegenerative component, with gray matter (GM) atrophy being an important contributor to disability. Optical coherence tomography (OCT) may serve as a prognostic tool for neuroaxonal health by measuring ganglion cell inner plexiform layer (GCIPL) thi...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.04.001

    authors: Lichtman-Mikol S,Razmjou S,Yarraguntla K,Bao F,Santiago-Martinez C,Seraji-Bozorgzad N,Bernitsas E

    更新日期:2019-06-01 00:00:00

  • Functional recovery in multiple sclerosis patients undergoing rehabilitation programs is associated with plasma levels of hemostasis inhibitors.

    abstract:BACKGROUND:Increasing evidence for contribution of hemostasis components in multiple sclerosis (MS) has been reported. Hemostasis protein inhibitors display key regulatory roles, extending to regulation of innate immune response and inflammation, and promotion of blood-brain barrier integrity. Whereas the effects on he...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102319

    authors: Ziliotto N,Lamberti N,Manfredini F,Straudi S,Baroni M,Tisato V,Carantoni M,Secchiero P,Basaglia N,Marchetti G,Bernardi F

    更新日期:2020-09-01 00:00:00

  • Prevalence of multiple sclerosis in Health District III, Murcia, Spain.

    abstract:BACKGROUND:The prevalence of multiple sclerosis (MS) varies throughout the world, and available epidemiological data suggest a progressively increasing prevalence of MS in Spain. The objective of this study was to calculate MS prevalence in Health District III of the autonomous community of Murcia in Spain. METHODS:Th...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.06.003

    authors: Candeliere-Merlicco A,Valero-Delgado F,Martínez-Vidal S,Lastres-Arias Mdel C,Aparicio-Castro E,Toledo-Romero F,Villaverde-González R

    更新日期:2016-09-01 00:00:00

  • Access, delivery and perceived efficacy of physiotherapy and use of complementary and alternative therapies by people with progressive multiple sclerosis in the United Kingdom: An online survey.

    abstract:INTRODUCTION:All people with progressive MS in the United Kingdom should have access to physiotherapy through the National Health Service (NHS). However levels of access and delivery are unknown. Furthermore there is no research on perceived efficacy of physiotherapy or the use of complementary and alternative medicine...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.01.002

    authors: Campbell E,Coulter E,Mattison P,McFadyen A,Miller L,Paul L

    更新日期:2017-02-01 00:00:00

  • Forkhead box C1 gene variant causing glaucoma and small vessel angiopathy can mimic multiple sclerosis.

    abstract::A 34-year old Caucasian female was initially diagnosed with multiple small-vessel strokes at age 20 years which were etiologically classified as secondary to anti-phospholipid antibody syndrome (APS) although she had no history or laboratory data to suggest APS. Based on her MRI of brain findings, one of her neurologi...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.04.004

    authors: Avasarala JR,Jones JR,Rogers CR

    更新日期:2018-05-01 00:00:00

  • Safety liver profile of teriflunomide versus interferon β in multiple sclerosis: Systematic review and indirect comparison meta-analysis.

    abstract:OBJECTIVES:To compare the liver safety profile of interferon β (IFN β) and teriflunomide in patients with multiple sclerosis. METHODS:A network meta-analysis was carried out following the Cochrane Collaboration methodology. All trials comparing all types of IFN β with teriflunomide, or disease-modifying drugs, or plac...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.msard.2018.09.014

    authors: Salas PAO,Parra CO,Florez CEP,Goez LM,Velez-van-Meerbeke A,Rodriguez JH

    更新日期:2018-11-01 00:00:00

  • An overview of lipidomic analysis in different human matrices of multiple sclerosis.

    abstract::Multiple sclerosis is a chronic inflammatory and neurodegenerative disease of the central nervous system, and it is one of the most common neurological cause of disability in young adults. It is known that several factors contribute to increase the risk of development and pathogenesis of multiple sclerosis, nonetheles...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2020.102189

    authors: Ferreira HB,Neves B,Guerra IM,Moreira A,Melo T,Paiva A,Domingues MR

    更新日期:2020-09-01 00:00:00

  • Extratemporal herpes encephalitis during natalizumab treatment: A case report.

    abstract::Herpes simplex virus encephalitis (HSE) is a rare but often fatal disease if left untreated. MRI typically shows the characteristic findings of medial temporal lobe and insular involvement, while diagnosis in confirmed by CSF PCR. In immunocompromised state, HSE may have atypical clinical and radiological features. We...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.10.002

    authors: Haggiag S,Prosperini L,Galgani S,Pozzilli C,Pinnetti C

    更新日期:2016-11-01 00:00:00

  • Targeting macrophages by an aza-anthrapyrazole to ameliorate experimental autoimmune encephalomyelitis.

    abstract:BACKGROUND:Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease in the central nerve system, in which both innate and adaptive immune cells are involved. BBR3378, an aza-anthrapyrazole prevents experimental autoimmune encephalomyelitis (EAE), an inflammatory condition similar to MS, by antagonizing T...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102190

    authors: Lin B,Launder D,Bailey DY,Assifuah FK,Miller OA,Conti HR,Du J,Koffman BM

    更新日期:2020-08-01 00:00:00

  • Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment.

    abstract::Progressive multifocal leukoencephalopathy (PML) is the most feared complication when natalizumab (NAT) is used in the treatment of relapsing multiple sclerosis (MS). JC virus serologic status is a currently established risk factor for PML. When seroconversion occurs, NAT discontinuation should be based on a solid rat...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2015.04.005

    authors: Barroso B,Miquel M,Marasescu R,Demasles S,Krim E,Bonnan M

    更新日期:2015-07-01 00:00:00

  • Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study.

    abstract:BACKGROUND:Growing evidence supports the efficacy of restorative cognitive training in people with multiple sclerosis (PwMS), but the effects vary across individuals. Differences in treatment efficacy may be related to baseline individual differences. We investigated clinical characteristics and MRI variables to predic...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.06.026

    authors: Fuchs TA,Ziccardi S,Dwyer MG,Charvet LE,Bartnik A,Campbell R,Escobar J,Hojnacki D,Kolb C,Oship D,Pol J,Shaw MT,Wojcik C,Yasin F,Weinstock-Guttman B,Zivadinov R,Benedict RHB

    更新日期:2019-09-01 00:00:00

  • A case of Takotsubo syndrome during a multiple sclerosis brainstem relapse.

    abstract:BACKGROUND:We report a case of a woman affected by relapsing remitting Multiple Sclerosis who developed acute left ventricular dysfunction in the context of a severe brainstem relapse, one month after an attempt of in-vitro fertilization. DISCUSSION:The characteristics of our case are consistent with the hypothesis of...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.05.005

    authors: Prestipino E,Squitieri M,Razzolini L,Pastò L,Forleo P,Amato MP

    更新日期:2018-08-01 00:00:00

  • A case-control study of dietary salt intake in pediatric-onset multiple sclerosis.

    abstract:BACKGROUND:High salt intake may be associated with pro-inflammatory changes in the immune response, and increased clinical and MRI activity in adults with relapsing-remitting multiple sclerosis. OBJECTIVE:We sought to determine if dietary salt intake is associated with pediatric-onset MS risk in a multicenter, case-co...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.msard.2016.02.011

    authors: McDonald J,Graves J,Waldman A,Lotze T,Schreiner T,Belman A,Greenberg B,Weinstock-Guttman B,Aaen G,Tillema JM,Hart J,Lulu S,Ness J,Harris Y,Rubin J,Candee M,Krupp LB,Gorman M,Benson L,Rodriguez M,Chitnis T,Mar S

    更新日期:2016-03-01 00:00:00

  • To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis.

    abstract:BACKGROUND:The frequency and long-term prognosis of relapsing multiple sclerosis (RMS) never receiving disease-modifying treatment (DMT) is unclear. METHODS:We included 1186 RMS patients with a mean of 17.4 years follow-up and divided them into patients treated with any DMT (DMT) and patients untreated by shared (USD)...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.101908

    authors: Bsteh G,Hegen H,Dosser C,Auer M,Berek K,Wurth S,Zinganell A,Di Pauli F,Deisenhammer F,Berger T

    更新日期:2019-12-23 00:00:00

  • Impaired central drive to plantarflexors and minimal ankle proprioceptive deficit in people with multiple sclerosis.

    abstract:BACKGROUND:A common and disruptive symptom of multiple sclerosis is difficulty in walking. Deficits in ankle proprioception and in plantarflexor muscle function may contribute to these mobility issues. In this study, ankle proprioceptive ability and plantarflexor performance of people with multiple sclerosis (PwMS) wer...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102584

    authors: Djajadikarta ZJ,Dongés SC,Brooks J,Kennedy DS,Gandevia SC,Taylor JL

    更新日期:2020-11-01 00:00:00

  • Are fatigue scales the same? A content comparison using the International Classification of Functioning, Disability and Health.

    abstract:BACKGROUND:Fatigue is a common impairment in a wide range of disorders. Numerous fatigue scales have been designed in an attempt to quantify this impairment without any clear distinction between them. The International Classification of Functioning, Disability and Health (ICF) is a useful tool for content comparison of...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102596

    authors: Alghwiri AA,Almhdawi KA,Marchetti G

    更新日期:2020-11-01 00:00:00

  • PER3 VNTR polymorphism in Multiple Sclerosis: A new insight to impact of sleep disturbances in MS.

    abstract:BACKGROUND:Multiple Sclerosis (MS) is a degenerative disease of central nervous system caused by an immune response against the myelin. About half of MS patients suffers from sleep disturbances. The circadian clock genes such as PER3 controls circadian rhythm and sleep. Due to the role of PER3 in sleep disturbances and...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.07.005

    authors: Golalipour M,Maleki Z,Farazmandfar T,Shahbazi M

    更新日期:2017-10-01 00:00:00

  • A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.

    abstract:BACKGROUND:Treatment decisions in patients with multiple sclerosis (MS) during the coronavirus disease 2019 (COVID-19) pandemic are challenging. It is not known whether and how various disease modifying therapies, especially immunosuppressive drugs, affect COVID-19 risk and disease course. METHODS:Case report RESULTS:...

    journal_title:Multiple sclerosis and related disorders

    pub_type:

    doi:10.1016/j.msard.2020.102182

    authors: Valencia-Sanchez C,Wingerchuk DM

    更新日期:2020-07-01 00:00:00